A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1st line ct in mbc pts

Autor:	H. Samonnig, G. Georgoulias, S. Van Belle, Y. Boudraa, F Van Aelst, H. Hausmaninger, C Zielinsky, Robert Paridaens, N. Azli, P. Willemse
Rok vydání:	1999
Předmět:	Cancer Research Oncology Randomized controlled trial Docetaxel law business.industry medicine Doxorubicin Pharmacology Line (text file) business law.invention medicine.drug
Zdroj:	European Journal of Cancer. 35:S314
ISSN:	0959-8049
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::68aa99a6514b0f4e91e3578e6ac035ca https://doi.org/10.1016/s0959-8049(99)81675-x Zobrazit plný text záznamu Full Text from ScienceDirect